Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Review
  • Published:

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

Leukemia volume 25, pages 7–22 (2011)Cite this article

Subjects

Abstract

Although only 5000 new cases of chronic myeloid leukemia (CML) were seen in the United States in 2009, this neoplasm continues to make scientific headlines year-after-year. Advances in understanding the molecular pathogenesis coupled with exciting developments in both drug design and development, targeting the initiating tyrosine kinase, have kept CML in the scientific limelight for more than a decade. Indeed, imatinib, a small-molecule inhibitor of the leukemia-initiating Bcr–Abl tyrosine kinase, has quickly become the therapeutic standard for newly diagnosed chronic phase-CML (CP-CML) patients. Yet, nearly one-third of patients will still have an inferior response to imatinib, either failing to respond to primary therapy or demonstrating progression after an initial response. Significant efforts geared toward understanding the molecular mechanisms of imatinib resistance have yielded valuable insights into the cellular biology of drug trafficking, enzyme structure and function, and the rational design of novel small molecule enzyme inhibitors. Indeed, new classes of kinase inhibitors have recently been investigated in imatinib-resistant CML. Understanding the pathogenesis of tyrosine kinase inhibitor resistance and the molecular rationale for the development of second and now third generation therapies for patients with CML will be keys to further disease control over the next 10 years.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Hehlmann R, Hochhaus A, Berger U, Reiter A . Current trends in the management of chronic myelogenous leukemia. Ann Hematol 2000; 79: 345–354.

    CAS  PubMed  Google Scholar 

  2. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417.

    Article  CAS  PubMed  Google Scholar 

  3. Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP et al. International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. ASH Annual Meeting Abstracts 2009; 114: 1126.

    Google Scholar 

  4. Guilhot F, Roy L, Guilhot J, Krahnke T, Guerci A, Druker B et al. Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP). ASH Annual Meeting Abstracts 2005; 106: 165.

    Google Scholar 

  5. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809–1820.

    Article  CAS  PubMed  Google Scholar 

  6. National Comprehensive Cancer Network (NCCN). Clinical Practive Guidelines in Oncology. Chronic Myelogenous Leukemia. National Comprehensive Cancer Network: Jenkintown, PA, vol. 1, 2009.

  7. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041–6051.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Apperley JF . Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8: 1018–1029.

    CAS  PubMed  Google Scholar 

  9. de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26: 3358–3363.

    Article  PubMed  Google Scholar 

  10. Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010; 28: 424–430.

    Article  CAS  PubMed  Google Scholar 

  11. Palandri F, Castagnetti F, Iacobucci I, Amabile M, Gugliotta G, Poerio A et al. The Combination of Interferon-Alpha with Imatinib in Early Chronic Phase Chronic Myeloid Leukemia Patients Induces a Significant Improvement of the Molecular Responses in the First Two Years of Treatment: Results From Three Studies From the GIMEMA CML Working Party. ASH Annual Meeting Abstracts 2009; 114: 2192.

    Google Scholar 

  12. Hehlmann R, Jung-Munkwitz S, Lauseker M, Leitner A, Pletsch N, Shazi S et al. Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg ± IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV. ASH Annual Meeting Abstracts 2009; 114: 339.

    Google Scholar 

  13. Guilhot F, Preudhomme C, Guilhot J, Mahon F-X, Nicolini FE, Rigual-Huguet F et al. Significant Higher Rates of Undetectable Molecular Residual Disease and Molecular Responses with Pegylated Form of Interferon a2a in Combination with Imatinib (IM) for the Treatment of Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukaemia (CML) Patients (pts): Confirmatory Results at 18 Months of Part 1 of the Spirit Phase III Randomized Trial of the French CML Group (FI LMC). ASH Annual Meeting Abstracts 2009; 114: 340.

    Google Scholar 

  14. Lucas CM, Wang L, Austin GM, Knight K, Watmough SJ, Shwe KH et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 2008; 22: 1963–1966.

    CAS  PubMed  Google Scholar 

  15. Alvarado Y, Kantarjian H, O'Brien S, Faderl S, Borthakur G, Burger J et al. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 2009; 115: 3709–3718.

    CAS  PubMed  Google Scholar 

  16. Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H, Reid AG et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008; 112: 4437–4444.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009; 113: 2154–2160.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Quintas-Cardama A, Cortes JE, O'Brien S, Ravandi F, Borthakur G, Liu D et al. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 2009; 115: 2912–2921.

    CAS  PubMed  Google Scholar 

  19. Lugo TG, Pendergast AM, Muller AJ, Witte ON . Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079–1082.

    CAS  PubMed  Google Scholar 

  20. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–566.

    CAS  PubMed  Google Scholar 

  21. Daley GQ, Van Etten RA, Baltimore D . Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824–830.

    CAS  PubMed  Google Scholar 

  22. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28–37.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Weisberg E, Griffin JD . Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000; 95: 3498–3505.

    CAS  PubMed  Google Scholar 

  24. le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95: 1758–1766.

    CAS  PubMed  Google Scholar 

  25. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070–1079.

    CAS  PubMed  Google Scholar 

  26. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880.

    CAS  PubMed  Google Scholar 

  27. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J . Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289: 1938–1942.

    CAS  PubMed  Google Scholar 

  28. O'Hare T, Eide CA, Deininger MW . Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110: 2242–2249.

    CAS  PubMed  Google Scholar 

  29. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117–125.

    CAS  PubMed  Google Scholar 

  30. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002; 100: 1014–1018.

    CAS  PubMed  Google Scholar 

  31. Nicolini FE, Corm S, Le QH, Sorel N, Hayette S, Bories D et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 2006; 20: 1061–1066.

    CAS  PubMed  Google Scholar 

  32. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006; 20: 1767–1773.

    CAS  PubMed  Google Scholar 

  33. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276–283.

    CAS  PubMed  Google Scholar 

  34. Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106: 2128–2137.

    CAS  PubMed  Google Scholar 

  35. Hochhaus A, Branford S, Radich J, Mueller MC, Shah N, Erben P et al. Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR- ABL mutations. J Clin Oncol (Meeting Abstracts) 2007; 25 (Suppl 18): 7023.

    Google Scholar 

  36. Kantarjian H, Pasquini R, Levy V, Jootar S, Holowiecki J, Hamerschlak N et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009; 115: 4136–4147.

    CAS  PubMed  Google Scholar 

  37. Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007; 109: 4143–4150.

    CAS  PubMed  Google Scholar 

  38. Cortes J, Kim DW, Raffoux E, Martinelli G, Ritchie E, Roy L et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008; 22: 2176–2183.

    CAS  PubMed  Google Scholar 

  39. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110: 3540–3546.

    CAS  PubMed  Google Scholar 

  40. le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008; 111: 1834–1839.

    CAS  PubMed  Google Scholar 

  41. Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009; 27: 469–471.

    CAS  PubMed  Google Scholar 

  42. Laneuville P, Dilea C, Yin OQ, Woodman RC, Mestan J, Manley PW . Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia. J Clin Oncol 2010; 28: e169–e171; author reply e172.

    CAS  PubMed  Google Scholar 

  43. Branford S, Melo JV, Hughes TP . Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 2009; 114: 5426–5435.

    CAS  PubMed  Google Scholar 

  44. La Rosee P, Hochhaus A . Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia. Curr Opin Hematol 2010; 17: 91–96.

    CAS  PubMed  Google Scholar 

  45. Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, Feldhahn N et al. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell 2009; 16: 232–245.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. McWeeney SK, Pemberton LC, Loriaux MM, Vartanian K, Willis SG, Yochum G et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood 2010; 115: 315–325.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B, Keri G . Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta 2002; 1587: 318–325.

    CAS  PubMed  Google Scholar 

  48. Che XF, Nakajima Y, Sumizawa T, Ikeda R, Ren XQ, Zheng CL et al. Reversal of P-glycoprotein mediated multidrug resistance by a newly synthesized 1,4-benzothiazipine derivative, JTV-519. Cancer Lett 2002; 187: 111–119.

    CAS  PubMed  Google Scholar 

  49. Kotaki M, Motoji T, Takanashi M, Wang YH, Mizoguchi H . Anti-proliferative effect of the abl tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562/ADM cell line. Cancer Lett 2003; 199: 61–68.

    CAS  PubMed  Google Scholar 

  50. Rumpold H, Wolf AM, Gruenewald K, Gastl G, Gunsilius E, Wolf D . RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. Exp Hematol 2005; 33: 767–775.

    CAS  PubMed  Google Scholar 

  51. Widmer N, Rumpold H, Untergasser G, Fayet A, Buclin T, Decosterd LA . Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels. Leukemia 2007; 21: 1561–1562; author reply 1562-1564.

    CAS  PubMed  Google Scholar 

  52. Lange T, Gunther C, Kohler T, Krahl R, Musiol S, Leiblein S et al. High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. Blood 2003; 101: 2152–2155.

    CAS  PubMed  Google Scholar 

  53. Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE . hOCT 1 and resistance to imatinib. Blood 2005; 106: 1133–1134; author reply 1134.

    CAS  PubMed  Google Scholar 

  54. Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008; 112: 2024–2027.

    CAS  PubMed  Google Scholar 

  55. Mountford J, Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S et al. Nilotinib concentration in Cell Lines and CML CD34+ Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters. ASH Annual Meeting Abstracts 2008; 112: 3205.

    Google Scholar 

  56. Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 2008; 68: 9809–9816.

    CAS  PubMed  Google Scholar 

  57. Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S, Harris RJ et al. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 2009; 23: 1999–2006.

    CAS  PubMed  Google Scholar 

  58. Hiwase DK, White D, Zrim S, Saunders V, Melo JV, Hughes TP . Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy. Leukemia 2010; 24: 658–660.

    CAS  PubMed  Google Scholar 

  59. White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006; 108: 697–704.

    CAS  PubMed  Google Scholar 

  60. Thomas J, Wang L, Clark RE, Pirmohamed M . Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739–3745.

    CAS  PubMed  Google Scholar 

  61. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE . Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008; 83: 258–264.

    CAS  PubMed  Google Scholar 

  62. White DL, Saunders VA, Dang P, Frede A, Eadie L, Soverini S et al. CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study. ASH Annual Meeting Abstracts 2008; 112: 3187.

    Google Scholar 

  63. White DL, Saunders VA, Frede A, Dang P, Zrim S, Osborn MP et al. The Functional Activity of the OCT-1 Protein Is Predictive of Molecular Response and Survival in CP-CML Patients Treated with Imatinib: A 5 Year Update of the TIDEL Trial. ASH Annual Meeting Abstracts 2009; 114: 507.

    Google Scholar 

  64. Hiwase DK, White DL, Saunders VA, Dang P, Venables A, Eadie L et al. In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis. ASH Annual Meeting Abstracts 2007; 110: 1937.

    Google Scholar 

  65. Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 2008; 14: 3881–3888.

    CAS  PubMed  Google Scholar 

  66. le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 1999; 91: 163–168.

    CAS  PubMed  Google Scholar 

  67. Snead JL, O'Hare T, Adrian LT, Eide CA, Lange T, Druker BJ et al. Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood 2009; 114: 3459–3463.

    CAS  PubMed  PubMed Central  Google Scholar 

  68. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22: 935–942.

    Article  CAS  PubMed  Google Scholar 

  69. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008; 111: 4022–4028.

    CAS  PubMed  Google Scholar 

  70. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109: 3496–3499.

    CAS  PubMed  Google Scholar 

  71. Forrest DL, Trainor S, Brinkman RR, Barnett MJ, Hogge DE, Nevill TJ et al. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res 2009; 33: 271–275.

    CAS  PubMed  Google Scholar 

  72. Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008; 14: 485–493.

    CAS  PubMed  Google Scholar 

  73. Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21: 926–935.

    CAS  PubMed  Google Scholar 

  74. Weinstein IB . Cancer. Addiction to oncogenes—the Achilles heal of cancer. Science 2002; 297: 63–64.

    CAS  PubMed  Google Scholar 

  75. Savona M, Talpaz M . Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer 2008; 8: 341–350.

    CAS  PubMed  Google Scholar 

  76. Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M . Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res 1996; 56: 3589–3596.

    CAS  PubMed  Google Scholar 

  77. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690–698.

    CAS  PubMed  Google Scholar 

  78. Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM . Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 2004; 10: 1187–1189.

    CAS  PubMed  Google Scholar 

  79. Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 2008; 100: 926–939.

    CAS  PubMed  PubMed Central  Google Scholar 

  80. Wu J, Meng F, Lu H, Kong L, Bornmann W, Peng Z et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood 2008; 111: 3821–3829.

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Stanglmaier M, Warmuth M, Kleinlein I, Reis S, Hallek M . The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains. Leukemia 2003; 17: 283–289.

    CAS  PubMed  Google Scholar 

  82. Meyn III MA, Wilson MB, Abdi FA, Fahey N, Schiavone AP, Wu J et al. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity. J Biol Chem 2006; 281: 30907–30916.

    CAS  PubMed  Google Scholar 

  83. Cortez D, Reuther G, Pendergast AM . The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 1997; 15: 2333–2342.

    CAS  PubMed  Google Scholar 

  84. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993; 75: 175–185.

    CAS  PubMed  Google Scholar 

  85. Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW . Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 1994; 84: 2912–2918.

    CAS  PubMed  Google Scholar 

  86. Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K et al. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 2002; 1: 479–492.

    CAS  PubMed  Google Scholar 

  87. Aceves-Luquero CI, Agarwal A, Callejas-Valera JL, Arias-Gonzalez L, Esparis-Ogando A, del Peso Ovalle L et al. ERK2, but not ERK1, mediates acquired and ‘de novo’ resistance to imatinib mesylate: implication for CML therapy. PLoS One 2009; 4: e6124.

    PubMed  PubMed Central  Google Scholar 

  88. Chai SK, Nichols GL, Rothman P . Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 1997; 159: 4720–4728.

    CAS  PubMed  Google Scholar 

  89. de Groot RP, Raaijmakers JA, Lammers JW, Jove R, Koenderman L . STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood 1999; 94: 1108–1112.

    CAS  PubMed  Google Scholar 

  90. Chen J, Odenike O, Rowley JD . Leukaemogenesis: more than mutant genes. Nat Rev Cancer 2010; 10: 23–36.

    CAS  PubMed  PubMed Central  Google Scholar 

  91. Lee SM, Bae JH, Kim MJ, Lee HS, Lee MK, Chung BS et al. Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors. J Pharmacol Exp Ther 2007; 322: 1084–1092.

    CAS  PubMed  Google Scholar 

  92. Kircher B, Schumacher P, Petzer A, Hoflehner E, Haun M, Wolf AM et al. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro. Eur J Haematol 2009; 83: 48–56.

    CAS  PubMed  Google Scholar 

  93. Fiskus W, Pranpat M, Bali P, Balasis M, Kumaraswamy S, Boyapalle S et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 2006; 108: 645–652.

    CAS  PubMed  Google Scholar 

  94. Guilhot F, Dubruille V, Skotnicki AB, Hellmann A, Shamsazar J, Bourquelot PM et al. A Phase II Study of Oral Panobinostat (LBH589) in Accelerated Phase (AP) or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Patients Resistant to ≥2 BCR-ABL Tyrosine Kinase Inhibitors. ASH Annual Meeting Abstracts 2008; 112: 4263.

    Google Scholar 

  95. Zaritskey A, Alimena G, Konopka L, Shamsazar J, Bourquelot PM, Jalaluddin M et al. A Phase II Study of Oral Panobinostat (LBH589) for Chronic Phase Chronic Myeloid Leukemia (CML) with Resistance to ⩾2 BCR-ABL Tyrosine Kinase Inhibitors. ASH Annual Meeting Abstracts 2008; 112: 4254.

    Google Scholar 

  96. Bhatia R, Snyder DS, Lin A, Arceo J, Seymour L, Deininger M et al. A Phase I Study of the HDAC Inhibitor LBH589 in Combination with Imatinib for Patients with CML in Cytogenetic Remission with Residual Disease Detectable by Q-PCR. ASH Annual Meeting Abstracts 2009; 114: 2194.

    Google Scholar 

  97. Oki Y, Kantarjian HM, Gharibyan V, Jones D, O'Brien S, Verstovsek S et al. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 2007; 109: 899–906.

    CAS  PubMed  Google Scholar 

  98. Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 2005; 23: 3948–3956.

    CAS  PubMed  Google Scholar 

  99. Gratwohl A, Heim D . Current role of stem cell transplantation in chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009; 22: 431–443.

    PubMed  Google Scholar 

  100. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873–2878.

    CAS  PubMed  Google Scholar 

  101. Aoki E, Kantarjian H, O'Brien S, Talpaz M, Giles F, Garcia-Manero G et al. High-dose imatinib mesylate treatment in patients (Pts) with untreated early chronic phase (CP) chronic myeloid leukemia (CML): 2.5-year follow-up. J Clin Oncol (Meeting Abstracts) 2006; 24 (Suppl 18): 6535.

    Google Scholar 

  102. Hughes TP, Branford S, White DL, Reynolds J, Koelmeyer R, Seymour JF et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 2008; 112: 3965–3973.

    CAS  PubMed  Google Scholar 

  103. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658–6661.

    CAS  PubMed  Google Scholar 

  104. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129–141.

    CAS  PubMed  Google Scholar 

  105. Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22: 1200–1206.

    CAS  PubMed  Google Scholar 

  106. Kantarjian H, Giles F, Bhalla K, Pinilla J, Larson RA, Gattermann N et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study. J Clin Oncol (Meeting Abstracts) 2009; 27 (15S): 7029.

    Google Scholar 

  107. Giles FJ, le Coutre P, Bhalla K, Rosti G, Ossenkoppele G, Alimena G et al. A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib. J Clin Oncol (Meeting Abstracts) 2007; 25 (Suppl 18): 7038.

    Google Scholar 

  108. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251–2259.

    CAS  PubMed  Google Scholar 

  109. Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007; 110: 4005–4011.

    CAS  PubMed  Google Scholar 

  110. Soverini S, Gnani A, Colarossi S, Castagnetti F, Abruzzese E, Paolini S et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 2009; 114: 2168–2171.

    CAS  PubMed  Google Scholar 

  111. Laneuville P, DiLea C, Mestan J, Yin O, Woodman RC, Manley P . Comparative In vitro Cellular Data Alone Is Insufficient to Predict Clinical Responses and Guide Choice of BCR-ABL Inhibitor to Treat Imatinib-Resistant Chronic Myeloid Leukemia. ASH Annual Meeting Abstracts 2009; 114: 510.

    Google Scholar 

  112. Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110: 4055–4063.

    CAS  PubMed  Google Scholar 

  113. Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C et al. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 2009; 114: 2037–2043.

    CAS  PubMed  PubMed Central  Google Scholar 

  114. Soverini S, Gnani A, Colarossi S, Castagnetti F, Abruzzese E, Paolini S et al. Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 2009; 114: 2168–2171.

    CAS  PubMed  Google Scholar 

  115. Khorashad JS, Milojkovic D, Mehta P, Anand M, Ghorashian S, Reid AG et al. In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood 2008; 111: 2378–2381.

    CAS  PubMed  Google Scholar 

  116. Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007; 117: 2562–2569.

    CAS  PubMed  PubMed Central  Google Scholar 

  117. Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 2007; 92: 401–404.

    CAS  PubMed  Google Scholar 

  118. Soverini S, Martinelli G, Colarossi S, Gnani A, Rondoni M, Castagnetti F et al. Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL. Lancet Oncol 2007; 8: 273–274.

    PubMed  Google Scholar 

  119. Gratwohl A, Hermans J, Niederwieser D, Frassoni F, Arcese W, Gahrton G et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1993; 12: 509–516.

    CAS  PubMed  Google Scholar 

  120. Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007; 109: 4686–4692.

    CAS  PubMed  Google Scholar 

  121. Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010; 115: 1880–1885.

    CAS  PubMed  Google Scholar 

  122. Venepalli N, Rezvani K, Mielke S, Savani BN . Role of allo-SCT for CML in 2010. Bone Marrow Transplant 2010, [E-pub ahead of print 7 June 2010]. PMID: 20531284.

  123. Tam CS, Kantarjian H, Garcia-Manero G, Borthakur G, O'Brien S, Ravandi F et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 2008; 112: 516–518.

    CAS  PubMed  PubMed Central  Google Scholar 

  124. Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006; 66: 11314–11322.

    CAS  PubMed  Google Scholar 

  125. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009; 23: 477–485.

    CAS  PubMed  Google Scholar 

  126. Cortes J, Kantarjian HM, Kim D-W, Khoury HJ, Turkina AG, Shen Z-X et al. Efficacy and Safety of Bosutinib (SKI-606) in Patients with Chronic Phase (CP) Ph+ Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib. ASH Annual Meeting Abstracts 2008; 112: 1098.

    Google Scholar 

  127. le Coutre P, Schwarz M, Kim TD . New developments in tyrosine kinase inhibitor therapy for newly diagnosed chronic myeloid leukemia. Clin Cancer Res 2010; 16: 1771–1780.

    CAS  PubMed  Google Scholar 

  128. Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 2008; 112: 53–55.

    CAS  PubMed  PubMed Central  Google Scholar 

  129. Rivera VM, Xu Q, Berk L, Keats J, Wardwell S, Wang F et al. Potent Antitumor Activity of AP24534, An Orally Active Inhibitor of Bcr-Abl, Flt3 and Other Kinases, in Both in Vitro and in Vivo Models of Acute Myeloid Leukemia (AML). ASH Annual Meeting Abstracts 2008; 112: 2932.

    Google Scholar 

  130. Rivera VM, Xu Q, Wang F, Snodgrass J, O'Hare T, Corbin AS et al. Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML). ASH Annual Meeting Abstracts 2007; 110: 1032.

    Google Scholar 

  131. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16: 401–412.

    CAS  PubMed  PubMed Central  Google Scholar 

  132. Talpaz M, Cortes J, Deininger M, Shah N, Flinn IW, Mauro MJ et al. Phase I trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and hematologic malignancies. J Clin Oncol 2010; 28: 6511 [abstract].

    Google Scholar 

  133. Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005; 106: 3948–3954.

    CAS  PubMed  Google Scholar 

  134. Kantarjian H, le Coutre P, Cortes J, Pinilla-Ibarz J, Nagler A, Hochhaus A et al. Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer 2010; 116: 2665–2672.

    CAS  PubMed  Google Scholar 

  135. Cortes J, Paquette R, Talpaz M, Pinilla J, Asatiani E, Wetzler M et al. Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph++ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation. ASH Annual Meeting Abstracts 2008; 112: 3232.

    Google Scholar 

  136. Cortes J . When Imatinib Fails, What Else Is There? American Society of Clinical Oncology 2009 Educational Book 2009; 45th Annual Meeting: 402–406.

  137. Kitzen JJ, de Jonge MJ, Verweij J . Aurora kinase inhibitors. Crit Rev Oncol Hematol 2010; 73: 99–110.

    CAS  PubMed  Google Scholar 

  138. Steeghs N, Mathijssen RH, Wessels JA, de Graan AJ, van der Straaten T, Mariani M et al. Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib. Invest New Drugs 2010; [E-pub ahead of print 25 February 2010] PMID: 20182906.

  139. Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 2008; 111: 4355–4364.

    CAS  PubMed  Google Scholar 

  140. Cortes-Franco J, Dombret H, Schafhausen P, Brummendorf TH, Boissel N, Latini F et al. Danusertib Hydrochloride (PHA-739358), a Multi-Kinase Aurora Inhibitor, Elicits Clinical Benefit in Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. ASH Annual Meeting Abstracts 2009; 114: 864.

    Google Scholar 

  141. Foran JM, Ravandi F, O'Brien SM, Borthakur G, Rios M, Boone P et al. Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia. J Clin Oncol (Meeting Abstracts) 2008; 26 (Suppl 15): 2518.

    Google Scholar 

  142. Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem 2009; 52: 379–388.

    CAS  PubMed  Google Scholar 

  143. Cortes J, Roboz GJ, Kantarjian HM, Feldman EJ, Karp JE, Pratz KW et al. A Phase I Dose Escalation Study of KW-2449, An Oral Multi-Kinase Inhibitor against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, ALL and MDS or Resistant/Intolerant CML. ASH Annual Meeting Abstracts 2008; 112: 2967.

    Google Scholar 

  144. Shiotsu Y, Kiyoi H, Ishikawa Y, Tanizaki R, Shimizu M, Umehara H et al. KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood 2009; 114: 1607–1617.

    CAS  PubMed  Google Scholar 

  145. Pratz KW, Stine A, Karp J, Small D, Cortez J, Roboz G et al. Optimizing the dose and schedule of KW-2449, FLT3/Aurora inhibitor, through analysis of in vivo target inhibition. J Clin Oncol (Meeting Abstracts) 2008; 26 (Suppl 15): 7069.

    Google Scholar 

  146. Van Etten RA, Chan WW, Zaleskas VM, Walz C, Evangelista P, Lazarides K et al. Switch Pocket Inhibitors of the ABL Tyrosine Kinase: Distinct Kinome Inhibition Profiles and in Vivo Efficacy in Mouse Models of CML and B-Lymphoblastic Leukemia Induced by BCR-ABL T315I. ASH Annual Meeting Abstracts 2008; 112: 576.

    Google Scholar 

  147. Cortes-Franco J, Raghunadharao D, Parikh P, Wetzler M, Lipton JH, Jones D et al. Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors - Results of A Multicenter Phase 2/3 Study. ASH Annual Meeting Abstracts 2009; 114: 861.

    Google Scholar 

  148. Cortes-Franco J, Khoury HJ, Nicolini FE, Corm S, Lipton JH, Jones D et al. Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutation-Results of An Ongoing Multicenter Phase 2/3 Study. ASH Annual Meeting Abstracts 2009; 114: 644.

    Google Scholar 

  149. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260–2270.

    CAS  PubMed  Google Scholar 

  150. Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010; 28: 398–404.

    CAS  PubMed  Google Scholar 

  151. Shah NP, Kantarjian HM, Kim DW, Rea D, Dorlhiac-Llacer PE, Milone JH et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008; 26: 3204–3212.

    CAS  PubMed  Google Scholar 

  152. Kantarjian H, Cortes J, Kim DW, Dorlhiac-Llacer P, Pasquini R, DiPersio J et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009; 113: 6322–6329.

    CAS  PubMed  PubMed Central  Google Scholar 

  153. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109: 3207–3213.

    CAS  PubMed  Google Scholar 

  154. Saglio G, Hochhaus A, Goh YT, Masszi T, Pasquini R, Maloisel F et al. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer 2010; 116: 3852–3861.

    CAS  PubMed  Google Scholar 

  155. Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol 2010; 85: 164–170.

    CAS  PubMed  Google Scholar 

  156. Quintas-Cardama A, Kantarjian H, Jones D, Nicaise C, O'Brien S, Giles F et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007; 109: 497–499.

    CAS  PubMed  Google Scholar 

  157. Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010; 28: 392–397.

    CAS  PubMed  Google Scholar 

  158. Rosti G, Castagnetti F, Palandri F, Breccia M, Leveto L, Gugliotta G et al. Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party. Blood 2009; 114: 2205 (abstract).

    Google Scholar 

  159. Giles FJ, Abruzzese E, Rosti G, Kim DW, Bhatia R, Bosly A et al. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia 2010; 24: 1299–1301.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA

    D Bixby & M Talpaz

Authors
  1. D Bixby
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Talpaz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Talpaz.

Ethics declarations

Competing interests

Bixby, Dale MD PhD reports that he is on the speakers bureau for Novartis. Talpaz, Moshe MD reports that he is on the speakers bureau for Novartis and receives grant support from Novartis, Bristol-Myers Squibb, Exelixis and Merck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bixby, D., Talpaz, M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 25, 7–22 (2011). https://doi.org/10.1038/leu.2010.238

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2010.238

Keywords

This article is cited by

Search

Advanced search

Quick links